MCID: BLD039
MIFTS: 34

Bladder Adenocarcinoma malady

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Bladder Adenocarcinoma

Aliases & Descriptions for Bladder Adenocarcinoma:

Name: Bladder Adenocarcinoma 12 14 69
Bladder Adenocarcinoma, Not Otherwise Specified 12
Adenocarcinoma of the Urinary Bladder 12
Adenocarcinoma of Bladder 12
Adenocarcinoma Bladder 52

Classifications:



External Ids:

Disease Ontology 12 DOID:3711
NCIt 47 C39836 C4032
SNOMED-CT 64 255110003
UMLS 69 C0279682

Summaries for Bladder Adenocarcinoma

Disease Ontology : 12 A bladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Bladder Adenocarcinoma, also known as bladder adenocarcinoma, not otherwise specified, is related to pelvic lipomatosis and bladder clear cell adenocarcinoma, and has symptoms including dysuria An important gene associated with Bladder Adenocarcinoma is CDX2 (Caudal Type Homeobox 2), and among its related pathways/superpathways are Primary Focal Segmental Glomerulosclerosis FSGS and Preimplantation Embryo. The drugs Fesoterodine and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include lung, liver and colon.

Related Diseases for Bladder Adenocarcinoma

Diseases related to Bladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 75)
id Related Disease Score Top Affiliating Genes
1 pelvic lipomatosis 11.0
2 bladder clear cell adenocarcinoma 10.9
3 bladder signet ring cell adenocarcinoma 10.9
4 adenocarcinoma 10.3
5 brachydactyly small stature face anomalies 10.2 MKI67 PCNA
6 oro-mandibular-limb hypogenesis syndrome 10.2 MKI67 PCNA
7 common bile duct neoplasm 10.2 MKI67 PCNA
8 lichen planus pigmentosus 10.2 MKI67 PCNA
9 lung adenoid cystic carcinoma 10.1 MKI67 PCNA
10 his bundle tachycardia 10.1 CDX2 MKI67
11 subependymal glioma 10.1 KRT20 MKI67
12 appendix mucinous cystadenocarcinoma 10.1 KRT20 PCNA
13 peritoneal benign neoplasm 10.1 CDX2 KRT20
14 dystonia 10.1 CDX2 KRT20
15 anal canal paget's disease 10.1 CDX2 KRT20
16 clitoris cancer 10.1 CDX2 KRT20
17 cervix endometriosis 10.1 CDX2 KRT20
18 apocrine adenocarcinoma 10.1 CDX2 KRT20
19 mucosal melanoma 10.1 CDX2 KRT20
20 neuroendocrine tumor 10.1 CDX2 KRT20
21 neurofibrosarcoma 10.1 CDX2 KRT20
22 myotonia congenita 10.1 CDX2 KRT20
23 spastic ataxia 5 10.1 CDX2 KRT20
24 pelvic inflammatory disease 10.1 CDX2 KRT20
25 anemia of prematurity 10.1 CDX2 KRT20
26 giant cell tumor 10.1 CDX2 KRT20
27 uterine corpus endometrial stromal sarcoma 10.1 GATA3 KRT20
28 mesenchymoma 10.1 CDX2 KRT20
29 papillary adenofibroma 10.1 CDX2 KRT20
30 hunter macpherson syndrome 10.1 CDX2 KRT20
31 sagittal sinus thrombosis 10.1 CDX2 KRT20
32 tabes dorsalis 10.1 CDX2 KRT20
33 churg-strauss syndrome 10.1 CDX2 KRT20
34 pacinian tumor 10.1 CDX2 KRT20
35 meninges hemangiopericytoma 10.1 CDX2 KRT20
36 gallbladder signet ring cell adenocarcinoma 10.1 CDX2 KRT20
37 neuroretinitis 10.1 CDX2 KRT20
38 acute stress disorder 10.0 CDX2 KRT20
39 acute retinal necrosis syndrome 10.0 CDX2 KRT20
40 allergic contact dermatitis 10.0 CDX2 KRT20
41 mitochondrial encephalomyopathy 10.0 KRT20 PCNA
42 ariboflavinosis 10.0 CDX2 KRT20
43 intestinal benign neoplasm 10.0 CDX2 KRT20
44 advanced sleep phase syndrome 10.0 CDX2 KRT20
45 fallopian tube adenocarcinoma 10.0 CDX2 KRT20
46 retrograde amnesia 10.0 MKI67 PCNA
47 pituitary carcinoma 10.0 CDX2 KRT20
48 steroid-induced glaucoma - borderline 10.0 KLK3 KRT20
49 odontotrichoungual-digital-palmar syndrome 10.0 CDX2 KRT20
50 colon signet ring adenocarcinoma 10.0 KLK3 KRT20

Graphical network of the top 20 diseases related to Bladder Adenocarcinoma:



Diseases related to Bladder Adenocarcinoma

Symptoms & Phenotypes for Bladder Adenocarcinoma

UMLS symptoms related to Bladder Adenocarcinoma:


dysuria

Drugs & Therapeutics for Bladder Adenocarcinoma

Drugs for Bladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 194)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
2
Nicotine Approved Phase 4 54-11-5 942 89594
3 Cholinergic Agents Phase 4
4 Cholinergic Antagonists Phase 4
5 Muscarinic Antagonists Phase 4
6 Neurotransmitter Agents Phase 4,Phase 2
7 Autonomic Agents Phase 4
8 Central Nervous System Stimulants Phase 4,Phase 1,Phase 2
9 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
10 Nicotinic Agonists Phase 4
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
12
Epirubicin Approved Phase 3 56420-45-2 41867
13
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
14
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
17
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
18
Oxaliplatin Approved, Investigational Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
19 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
20 Alkylating Agents Phase 3,Phase 2
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
22 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 3,Phase 2,Phase 1
24 Antiviral Agents Phase 3,Phase 2,Phase 1
25 BCG Vaccine Phase 3
26 Interferon-alpha Phase 3
27 interferons Phase 3,Phase 1,Phase 2
28 Mitomycins Phase 3,Phase 2
29 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
30 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
31 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
32 Vaccines Phase 3,Phase 1,Phase 2
33 Antimetabolites Phase 3,Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
35 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
36 Adjuvants, Anesthesia Phase 3
37 Analgesics Phase 3,Phase 2
38 Analgesics, Opioid Phase 3
39 Anesthetics Phase 3
40 Anesthetics, General Phase 3
41 Anesthetics, Intravenous Phase 3
42 Central Nervous System Depressants Phase 3
43 Narcotics Phase 3
44 pancreatic polypeptide Phase 3,Phase 1
45 Androgens Phase 3,Phase 1,Phase 2
46 Hormone Antagonists Phase 3
47 Hormones Phase 3,Phase 1,Phase 2
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
49 Cola Nutraceutical Phase 3,Phase 1,Phase 2
50
Ifosfamide Approved Phase 2 3778-73-2 3690

Interventional clinical trials:

(show top 50) (show all 134)
id Name Status NCT ID Phase
1 A Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy Completed NCT01661166 Phase 4
2 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
3 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3
4 Randomized Trial on Robotic Assisted Resection for Rectal Cancer Unknown status NCT01130233 Phase 3
5 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3
6 Image Guided Radiation Therapy For Prostate Cancer Completed NCT00433706 Phase 3
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
8 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3
9 Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients Recruiting NCT02303327 Phase 3
10 Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Recruiting NCT01470443 Phase 3
11 Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate Active, not recruiting NCT01444820 Phase 3
12 Radiotherapy - Adjuvant Versus Early Salvage Active, not recruiting NCT00860652 Phase 3
13 Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer Unknown status NCT01196403 Phase 2
14 A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma Unknown status NCT00183885 Phase 2
15 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
16 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2
17 Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Completed NCT00002684 Phase 2
18 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2
19 A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts Completed NCT01007552 Phase 2
20 Trial Evaluating the Efficacy of Laying a Biliary Stent for Producing a Heavy Chemotherapy in Unresectable Pancreatic Adenocarcinomas Completed NCT02487836 Phase 2
21 Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma Completed NCT00252941 Phase 1, Phase 2
22 Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer Completed NCT00075504 Phase 2
23 Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer Completed NCT00002602 Phase 1, Phase 2
24 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2
25 Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types Completed NCT00633789 Phase 2
26 High-dose ICE With Amifostine Completed NCT00003657 Phase 2
27 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2
28 Bupropion in Helping Adults Stop Smoking Completed NCT00534001 Phase 2
29 Zinc Supplements in Lowering Cadmium Levels in Smokers Completed NCT00376987 Phase 2
30 A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 Completed NCT00948961 Phase 1, Phase 2
31 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
32 Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology Recruiting NCT03092518 Phase 2
33 A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Recruiting NCT01928394 Phase 1, Phase 2
34 Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium Recruiting NCT00756639 Phase 2
35 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Recruiting NCT01631552 Phase 1, Phase 2
36 Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers Recruiting NCT02141490 Phase 2
37 A Study to Evaluate the Efficacy, and Safety of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer (UBC) or Pancreas/Cholangio Cancer (Kameleon Study Recruiting NCT02999672 Phase 2
38 Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06 Recruiting NCT01164150 Phase 2
39 A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors Recruiting NCT02886897 Phase 1, Phase 2
40 Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma Recruiting NCT02631590 Phase 2
41 A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers Recruiting NCT03115801 Phase 2
42 Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Recruiting NCT02646319 Phase 2
43 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting NCT02643303 Phase 1, Phase 2
44 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting NCT01174121 Phase 2
45 Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Active, not recruiting NCT00082706 Phase 2
46 Study of Tremelimumab in Patients With Advanced Solid Tumors Active, not recruiting NCT02527434 Phase 2
47 Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers Active, not recruiting NCT01148069 Phase 2
48 Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer Active, not recruiting NCT02031328 Phase 1, Phase 2
49 Cabozantinib for Advanced Urothelial Cancer Active, not recruiting NCT01688999 Phase 2
50 Hypofractionated Radiotherapy Versus Stereotactic Irradiation With Hyaluronic Acid Active, not recruiting NCT02361515 Phase 2

Search NIH Clinical Center for Bladder Adenocarcinoma

Genetic Tests for Bladder Adenocarcinoma

Anatomical Context for Bladder Adenocarcinoma

MalaCards organs/tissues related to Bladder Adenocarcinoma:

39
Lung, Liver, Colon

Publications for Bladder Adenocarcinoma

Articles related to Bladder Adenocarcinoma:

(show all 32)
id Title Authors Year
1
Urinary Bladder Adenocarcinoma Metastatic to the Abdominal Wall: Report of a Case with Cytohistologic Correlation. ( 27006847 )
2016
2
A novel treatment approach prolonging survival in an uncommon metastatic primary bladder adenocarcinoma. ( 26955660 )
2016
3
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. ( 27427223 )
2016
4
Anterior pelvic exenteration for exstrophic bladder adenocarcinoma: Case report and review. ( 27288750 )
2016
5
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. ( 27048257 )
2016
6
Mucinous Bladder Adenocarcinoma: Case Report and Literature Review. ( 26421206 )
2015
7
Gall bladder Adenocarcinoma in a Young Girl. ( 26139973 )
2015
8
Bladder metastasis from lung adenocarcinoma: a difficult differential diagnosis with primary bladder adenocarcinoma. ( 24716732 )
2014
9
Hepatobiliary and pancreatic: coexisting cancers: Hepatic neuroendocrine carcinomas with gall bladder adenocarcinoma. ( 25040620 )
2014
10
Co-occurrence of acanthosis nigricans and bladder adenocarcinoma - case report. ( 24596525 )
2013
11
[Bladder adenocarcinoma 41 years after augmentation enterocystoplasty for tuberculosis]. ( 23589601 )
2013
12
Complete Response of Primary Bladder Adenocarcinoma with the FOLFOX4 Regimen. ( 24281125 )
2013
13
Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge. ( 23121893 )
2012
14
Sweet's syndrome as the presenting manifestation of gall bladder adenocarcinoma. ( 23076693 )
2012
15
KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. ( 22804747 )
2012
16
Decoy cells and malignant cells coexisting in the urine from a transplant recipient with BK virus nephropathy and bladder adenocarcinoma. ( 22081531 )
2011
17
Coexisting metastatic choriocarcinoma and bladder adenocarcinoma of common germ cell origin. ( 22294067 )
2011
18
Bladder adenocarcinoma following gastrocystoplasty. ( 20392671 )
2010
19
In vivo reflectance confocal microscopy for cutaneous metastasis of bladder adenocarcinoma. ( 19221283 )
2009
20
Giant T4 rectal carcinoma mimicking urinary bladder adenocarcinoma accurately diagnosed by immunohistochemistry and successfully treated with total pelvic exenteration: report of a case. ( 18307003 )
2008
21
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer. ( 18604226 )
2008
22
Urinary bladder adenocarcinoma arising in a spina bifida patient. ( 18022132 )
2007
23
Leptomeningeal carcinomatosis from urinary bladder adenocarcinoma: a clinicopathological case study. ( 15822823 )
2005
24
Spontaneous resolution of bladder adenocarcinoma. ( 15160537 )
2003
25
Hepatocellular carcinoma and gall bladder adenocarcinoma: two primaries with no significant risk factors. ( 19861819 )
2003
26
Bladder adenocarcinoma: 31 reported cases. ( 11718635 )
2001
27
The prognostic importance of the nucleolar organizer region (AgNOR), Ki-67 and proliferating cell nuclear antigen (PCNA) in primary nonurachal bladder adenocarcinoma. ( 11506474 )
2001
28
Recurrent bladder adenocarcinoma in an ileal conduit stoma: a case report. ( 10510893 )
1999
29
Urine cytology of primary and secondary urinary bladder adenocarcinoma. ( 9915134 )
1998
30
Bladder adenocarcinoma during pregnancy: a case report. ( 8855078 )
1996
31
Adenocarcinoma in an ileal conduit: recurrence of bladder adenocarcinoma. ( 8389497 )
1993
32
Alpha-1-antitrypsin (AAT) deposits in gall bladder adenocarcinoma and liver in partial AAT deficiency (Pi SZ phenotype). ( 6983292 )
1982

Variations for Bladder Adenocarcinoma

Expression for Bladder Adenocarcinoma

Search GEO for disease gene expression data for Bladder Adenocarcinoma.

Pathways for Bladder Adenocarcinoma

Pathways related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.82 MKI67 PCNA
2 10.4 CDX2 GATA3

GO Terms for Bladder Adenocarcinoma

Biological processes related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell differentiation GO:0045597 8.62 CDX2 GATA3

Sources for Bladder Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....